X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (292) 292
life sciences & biomedicine (280) 280
humans (255) 255
administration, oral (244) 244
multiple sclerosis (238) 238
sphingosine - analogs & derivatives (120) 120
fingolimod hydrochloride (118) 118
pharmacology & pharmacy (112) 112
female (109) 109
animals (107) 107
multiple sclerosis, relapsing-remitting - drug therapy (106) 106
male (105) 105
immunosuppressive agents - administration & dosage (102) 102
multiple sclerosis - drug therapy (100) 100
immunosuppressive agents - therapeutic use (99) 99
neurosciences & neurology (98) 98
clinical neurology (90) 90
fingolimod (87) 87
adult (76) 76
propylene glycols - administration & dosage (73) 73
drug therapy (69) 69
immunosuppressive agents - adverse effects (65) 65
sphingosine - administration & dosage (65) 65
treatment outcome (64) 64
neurology (60) 60
propylene glycols - therapeutic use (58) 58
middle aged (55) 55
neurosciences (54) 54
sphingosine - therapeutic use (54) 54
propylene glycols - adverse effects (41) 41
dimethyl fumarate (40) 40
sphingosine - adverse effects (40) 40
clinical trials (39) 39
fty720 (38) 38
teriflunomide (38) 38
dosage and administration (37) 37
general & internal medicine (37) 37
medicine, general & internal (37) 37
dose-response relationship, drug (35) 35
mice (35) 35
young adult (35) 35
immunosuppressive agents - pharmacology (34) 34
oral administration (34) 34
care and treatment (33) 33
patients (32) 32
crotonates - therapeutic use (31) 31
disease progression (31) 31
toluidines - therapeutic use (31) 31
cladribine (30) 30
interferon (30) 30
magnetic resonance imaging (30) 30
propylene glycols - pharmacology (30) 30
research (30) 30
medicine & public health (29) 29
medicine (28) 28
rats (28) 28
fingolimod hydrochloride - therapeutic use (27) 27
lymphocytes (27) 27
receptors, lysosphingolipid - metabolism (27) 27
clinical trials as topic (26) 26
immunology (26) 26
review (26) 26
double-blind method (25) 25
sphingosine - pharmacology (25) 25
fingolimod hydrochloride - administration & dosage (24) 24
time factors (24) 24
immunologic factors - administration & dosage (23) 23
immunomodulation (23) 23
analysis (22) 22
drug dosages (22) 22
immunologic factors - therapeutic use (22) 22
pharmacokinetics (22) 22
psychiatry (22) 22
sphingosine (22) 22
abridged index medicus (21) 21
drugs (21) 21
fda approval (21) 21
laquinimod (21) 21
multiple sclerosis, relapsing-remitting - physiopathology (21) 21
adolescent (20) 20
cladribine - therapeutic use (20) 20
clinical trials, phase iii as topic (20) 20
crotonates - administration & dosage (20) 20
disability evaluation (20) 20
disease models, animal (20) 20
fumarates - therapeutic use (20) 20
immunosuppressive agents (20) 20
interferon-beta - therapeutic use (20) 20
receptors, lysosphingolipid - agonists (20) 20
safety (20) 20
sphingosine 1-phosphate (20) 20
studies (20) 20
toluidines - administration & dosage (20) 20
encephalomyelitis, autoimmune, experimental - drug therapy (19) 19
oral diseases (19) 19
health aspects (18) 18
immunosuppressive agents - pharmacokinetics (18) 18
inflammation (18) 18
multiple sclerosis, relapsing-remitting - diagnosis (18) 18
oral (18) 18
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (374) 374
German (9) 9
Spanish (5) 5
Hungarian (4) 4
French (2) 2
Japanese (2) 2
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 02/2010, Volume 362, Issue 5, pp. 402 - 415
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 02/2010, Volume 362, Issue 5, pp. 387 - 401
In this 24-month, randomized trial involving patients with relapsing–remitting multiple sclerosis, oral fingolimod reduced the rates of relapse and disability progression, as compared with placebo... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Arrhythmias, Cardiac - chemically induced | Herpesviridae Infections - etiology | Sphingosine - adverse effects | Herpesviridae Infections - mortality | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Young Adult | Propylene Glycols - adverse effects | Sphingosine - administration & dosage | Propylene Glycols - therapeutic use | Adult | Female | Immunosuppressive Agents - administration & dosage | Disability Evaluation | Liver Function Tests | Multiple Sclerosis, Relapsing-Remitting - pathology | Macular Edema - chemically induced | Double-Blind Method | Administration, Oral | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Kaplan-Meier Estimate | Fingolimod Hydrochloride | Disease Progression | Magnetic Resonance Imaging | Sphingosine - analogs & derivatives | Propylene Glycols - administration & dosage | Adolescent | Brain - pathology | Immunosuppressive Agents - adverse effects | Sphingosine - therapeutic use | Multiple sclerosis | Usage | Magnetic resonance imaging | Placebos | Dosage and administration | Diagnosis | Drug therapy | Comparative analysis | Immunosuppressive agents | Interferon | Manuscripts | Index Medicus | Abridged Index Medicus
Journal Article